Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Synthaverse SA (SVEP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.930 -0.020    -0.40%
06:05:30 - Delayed Data. Currency in PLN ( Disclaimer )
Type:  Equity
Market:  Poland
ISIN:  PLBMDLB00018 
  • Volume: 37,524
  • Bid/Ask: 4.920 / 4.930
  • Day's Range: 4.920 - 4.950
Synthaverse 4.930 -0.020 -0.40%

WA:SVEP Financials

 
A brief overview of the WA:SVEP financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Synthaverse SA over time.

Synthaverse S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was PLN 58.61 million compared to PLN 50.38 million a year ago. Net income was PLN 4.76 million compared to PLN 6.08 million a year ago. Basic earnings per share from continuing operations was PLN 0.07 compared to PLN 0.09 a year ago. Diluted earnings per share from continuing operations was PLN 0.07 compared to PLN 0.09 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SVEP Income Statement

Gross margin TTM 59.35%
Operating margin TTM 14.36%
Net Profit margin TTM 8.12%
Return on Investment TTM 3.94%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 20.15 8.1 18.36 12
Gross Profit 13.23 5.12 10.79 6.03
Operating Income 6.2 -2.94 4.08 1.3
Net Income 3.87 -2.42 2.56 0.742

SVEP Balance Sheet

Quick Ratio MRQ 0.7
Current Ratio MRQ 1.47
LT Debt to Equity MRQ 52.26%
Total Debt to Equity MRQ 62.18%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 265.9 226.9 193.95 173.59
Total Liabilities 153.26 119.71 84.33 67.3
Total Equity 112.64 107.19 109.62 106.29

SVEP Cash Flow Statement

Cash Flow/Share TTM -0.08
Revenue/Share TTM 0.83
Operating Cash Flow  7.97%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 2.47 -1.01 -6.38 -0.425
Cash From Investing Activities -22.08 -36.06 -13.41 -1.36
Cash From Financing Activities 14.96 31.31 7.64 -0.576
Net Change in Cash -4.65 -5.76 -12.15 -2.36
* In Millions of PLN (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SVEP Comments

Write your thoughts about Synthaverse SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jan Marcinkowski
Jan Marcinkowski Jul 14, 2020 7:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Right now its the most hyped company in Poland. Price could reach 30-100PLN
Ramba Łej
Kubizm Jul 14, 2020 7:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
And hype seems to be gone
Ramba Łej
Kubizm Jul 14, 2020 7:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ofc its still up from where it was in march im aware of it xD
Jan Chojnacki
Jan Chojnacki Jul 14, 2020 7:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ramba Łej will be 60
Ramba Łej
Kubizm Jul 14, 2020 7:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Jan Chojnacki  maybe some day:) for now I found a weak candle stick signals of bullish reversal with no confimartion on 1d timeframe. MACD sell, OBV sell, RSI 40 still plenty space to go down after triple peak over 80.
Ramba Łej
Kubizm Jul 06, 2020 4:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
basically speculation - maybe vaccine maybe not
Ramba Łej
Kubizm Jul 06, 2020 4:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I got burned with the same speculation with zynerba but on much further step toward fda approved but still just speculation.
Adam Smith
Adam Smith Jul 06, 2020 4:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The jus started test producion so its real.
Ramba Łej
Kubizm Jul 06, 2020 4:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Adam Smith  we will see "the reality" of this test product
Adam Smith
Adam Smith Jun 24, 2020 5:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Biotech company with know how and possibility to create maybe even medicine for COVID
Jan Marcinkowski
Jan Marcinkowski Jun 12, 2020 5:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BioMed company currently working on COVID vaccine in Poland
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email